Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18154 ↗At a glance
Beobachtungsstudie in Alimentary Pharmacology & Therapeutics, 2024. Written by Maria Ling Lundström and 18 co-authors. Institution: Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden. Major MEDLINE topics: Biomarkers, Feces, Leukocyte L1 Antigen Complex, Peroxidase. Cited 21 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Stiftelsen för Strategisk Forskning, Vetenskapsrådet, Örebro University Hospital Research Foundation.
Abstract (original language)
Background
Faecal biomarkers can be used to assess inflammatory bowel disease (IBD).
Aim
To explore the performance of some promising biomarkers in diagnosing and predicting disease course in IBD.
Methods
We included 65 patients with treatment‐naïve, new‐onset Crohn's disease (CD), 90 with ulcerative colitis (UC), 67 symptomatic controls (SC) and 41 healthy controls (HC) in this prospective observational study. We analysed faecal samples for calprotectin (FC), myeloperoxidase (MPO), human neutrophil lipocalin (HNL), eosinophil cationic protein ECP and eosinophil‐derived neurotoxin (EDN) and compared markers among groups. We assessed the diagnostic capability of biomarkers with receiver operating characteristic curves. Clinical disease course was determined for each patient with IBD and analysed the association with biomarkers by logistic regression.
Results
All markers were elevated at inclusion in patients with IBD compared with HC ( p < 0.001) and SC ( p < 0.001). FC (AUC 0.85, 95% CI: 0.79–0.89) and MPO (AUC 0.85, 95% CI: 0.80–0.89) showed the highest diagnostic accuracy in distinguishing IBD from SC. The diagnostic ability of biomarkers differed between IBD subtypes with the highest performance for FC and MPO in CD. The diagnostic accuracy was further improved by combining FC and MPO ( p = 0.02). Levels of FC, MPO and HNL at inclusion were predictive of an aggressive disease course with MPO showing the strongest association ( p = 0.006).
Conclusions
This study provides new insight into the diagnostic and prognostic capability of neutrophil and eosinophil biomarkers in IBD and suggests that MPO, alone or in combination with FC, may add to the diagnostic power of faecal biomarkers.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden.
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
- Karolinska Institute, Department of Medicine Solna, Stockholm, Sweden.
- Gastroenterology Unit, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
ORCID profiles: Maria Ling Lundström, Charlotte R H Hedin, Daniel Bergemalm, Lena Öhman, Jonas Halfvarson
Funding
- Stiftelsen för Strategisk Forskning
- Vetenskapsrådet
- Örebro University Hospital Research Foundation
- Medical Faculty, Uppsala University, Uppsala, Sweden MC
Cite
APA
Ling Lundström, M., Peterson, C., Hedin, C. R. H., Bergemalm, D., Lampinen, M., Magnusson, M. K., Keita, Å. V., Kruse, R., Lindqvist, C. M., Repsilber, D., D'Amato, M., Hjortswang, H., Strid, H., BIOIBD Consortium, Söderholm, J. D., Öhman, L., Venge, P., Halfvarson, J., & Carlson, M. (2024). Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18154
Vancouver
Ling Lundström M, Peterson C, Hedin CRH, Bergemalm D, Lampinen M, Magnusson MK, et al. Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18154
BibTeX
@article{LingLundstrm2024,
author = {Ling Lundström, Maria and Peterson, Christer and Hedin, Charlotte R H and Bergemalm, Daniel and Lampinen, Maria and Magnusson, Maria K and Keita, Åsa V and Kruse, Robert and Lindqvist, Carl Mårten and Repsilber, Dirk and D'Amato, Mauro and Hjortswang, Henrik and Strid, Hans and BIOIBD Consortium, BIOIBD Consortium and Söderholm, Johan D and Öhman, Lena and Venge, Per and Halfvarson, Jonas and Carlson, Marie},
title = {Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18154}
}
EUVIMED